Cargando…
Multimodality Treatment of Advanced Non-small Cell Lung Cancer: Where are we with the Evidence?
PURPOSE OF REVIEW: The majority of patients with non-small cell lung cancer (NSCLC) present with advanced disease and overall survival rates are poor. This article outlines the current and outstanding evidence for the use of multimodality treatment in this group of patients, including in combination...
Autores principales: | Jones, Christopher M., Brunelli, Alessandro, Callister, Matthew E., Franks, Kevin N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805813/ https://www.ncbi.nlm.nih.gov/pubmed/29456881 http://dx.doi.org/10.1007/s40137-018-0202-0 |
Ejemplares similares
-
Risk Stratification in Lung Resection
por: Salati, Michele, et al.
Publicado: (2016) -
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
por: Tak, Young Jin, et al.
Publicado: (2021) -
Introduction to sessions on 'Endocrine therapy: where have we come from, where are we at and where are we going to?'
por: Ingle, James N
Publicado: (2008) -
The Future of Paediatric Heart Interventions: Where Will We Be in 2030?
por: Kogure, Tomohito, et al.
Publicado: (2020) -
Editorial: Preoperative Frailty Risk Assessment Prior to Esophagectomy, Where Are We?
por: Fay, K. A., et al.
Publicado: (2023)